LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Ouvert

SecteurSoins de santé

2.15 -8.12

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.1

Max

2.33

Chiffres clés
By Trading Economics
Revenu	2.6M -39M
Employés	150
EBITDA	-1.4M -39M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+273.82% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	225M 787M
Ouverture précédente	10.27
Clôture précédente	2.15

Sentiment de l'Actualité

By Acuity

84%

16%

320 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.18 / 1.69 Support & Résistance

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 mai 2026, 22:54 UTC

Résultats

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 mai 2026, 23:17 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mai 2026, 23:16 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mai 2026, 23:15 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mai 2026, 23:14 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mai 2026, 23:02 UTC

Market Talk

Résultats

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mai 2026, 22:59 UTC

Market Talk

Résultats

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mai 2026, 22:24 UTC

Résultats

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mai 2026, 22:23 UTC

Résultats

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mai 2026, 22:23 UTC

Résultats

Xero FY International Revenue Growth 47%>XRO.AU

13 mai 2026, 22:22 UTC

Résultats

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mai 2026, 22:19 UTC

Résultats

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mai 2026, 22:19 UTC

Résultats

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mai 2026, 22:18 UTC

Résultats

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mai 2026, 22:16 UTC

Résultats

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mai 2026, 22:15 UTC

Résultats

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mai 2026, 22:15 UTC

Résultats

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mai 2026, 22:13 UTC

Résultats

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mai 2026, 22:12 UTC

Résultats

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mai 2026, 22:11 UTC

Résultats

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mai 2026, 22:11 UTC

Résultats

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mai 2026, 22:10 UTC

Résultats

Xero Did Not Declare a Dividend>XRO.AU

13 mai 2026, 22:10 UTC

Résultats

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mai 2026, 22:09 UTC

Résultats

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mai 2026, 22:00 UTC

Résultats

Cisco to Shed Jobs for All-In AI Push -- Update

13 mai 2026, 21:11 UTC

Résultats

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

273.82% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 273.82%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.18 / 1.69Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

320 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.